Eosinophils: Multifaceted Inflammatory Cells and Therapeutic Targets Beyond DRESS Syndrome

Abstract

Eosinophils, traditionally recognized for their role in parasitic infections and allergic diseases, have emerged as complex and multifaceted inflammatory cells implicated in a growing spectrum of pathological conditions. Beyond their well-established presence in diseases like asthma and atopic dermatitis, eosinophils are increasingly recognized as critical players in various inflammatory disorders, including drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, eosinophilic gastrointestinal diseases (EGIDs), and even certain cancers. This report provides a comprehensive overview of eosinophil biology, encompassing their development, activation mechanisms, and diverse effector functions in different tissues. We explore the roles of eosinophils in various inflammatory diseases, highlighting their mechanisms of action in tissue damage and repair. Furthermore, we critically evaluate the therapeutic implications of targeting eosinophils, particularly focusing on interleukin-5 (IL-5) inhibitors and other emerging strategies, while considering potential limitations and future directions in eosinophil-targeted therapies. We will explore how the specificity of these approaches can be refined to maximize efficacy while minimizing off-target effects, ultimately improving clinical outcomes for patients suffering from eosinophil-driven diseases.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Eosinophils, granulocytic leukocytes constituting a small fraction (1-6%) of circulating white blood cells, were first described by Wharton Jones in 1846 and subsequently characterized by Paul Ehrlich in 1879, who noted their unique affinity for acidic dyes like eosin. Initially, eosinophils were primarily associated with parasitic infections, a role supported by their ability to release cytotoxic proteins effective against helminths. However, the scope of eosinophil involvement has expanded significantly, revealing their crucial roles in a diverse range of physiological and pathological processes. These include allergic inflammation, tissue remodeling, immune regulation, and even anti-tumor immunity under certain circumstances [1, 2].

While beneficial in defense against parasites, eosinophil dysregulation is implicated in numerous inflammatory diseases. The classic example is allergic asthma, where eosinophils contribute to airway hyperresponsiveness, mucus production, and tissue damage. Similarly, eosinophilic esophagitis (EoE), a type of EGID, is characterized by dense eosinophil infiltration of the esophageal mucosa, leading to dysphagia and food impaction [3]. More recently, eosinophils have been identified as key players in DRESS syndrome, a severe drug-induced hypersensitivity reaction characterized by fever, rash, lymphadenopathy, and internal organ involvement [4]. These observations highlight the need for a deeper understanding of eosinophil biology and their contribution to various inflammatory pathologies.

Targeting eosinophils therapeutically has proven effective in certain conditions. IL-5 inhibitors, such as mepolizumab and reslizumab, effectively reduce eosinophil numbers and clinical symptoms in severe eosinophilic asthma and hypereosinophilic syndrome (HES) [5]. However, these therapies are not universally effective, and their impact on eosinophil function beyond simply reducing their numbers is still under investigation. Furthermore, the potential for unintended consequences of eosinophil depletion, particularly in the context of immune surveillance and tissue homeostasis, warrants careful consideration. This report aims to provide a comprehensive overview of eosinophil biology and their roles in various inflammatory diseases, focusing on the potential and limitations of current and emerging therapeutic strategies targeting eosinophils.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Eosinophil Development and Activation

2.1. Eosinophilopoiesis

The development of eosinophils, termed eosinophilopoiesis, is a complex process regulated by a network of cytokines and transcription factors. It primarily occurs in the bone marrow and is driven by the hematopoietic growth factor interleukin-5 (IL-5). IL-5, produced mainly by T helper 2 (Th2) cells, mast cells, and innate lymphoid cells (ILCs), binds to the IL-5 receptor α (IL-5Rα) expressed on eosinophil progenitors, triggering intracellular signaling cascades that promote their differentiation, survival, and maturation [6]. The IL-5Rα forms a heterodimeric receptor complex with the common β chain (CD131), which is also shared by the receptors for granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-3. This shared β chain explains some of the overlapping effects of these cytokines on eosinophil development and function.

Beyond IL-5, other cytokines such as GM-CSF and IL-3 contribute to eosinophilopoiesis, although their roles are generally considered less critical than that of IL-5. GM-CSF, in particular, can promote eosinophil survival and activation, while IL-3 can enhance eosinophil differentiation from early progenitor cells [7]. The transcription factor GATA-1 is essential for eosinophil development, regulating the expression of genes involved in eosinophil-specific functions [8]. Other transcription factors, including PU.1 and C/EBP family members, also play important roles in eosinophilopoiesis.

2.2. Eosinophil Activation

Eosinophils are activated by a variety of stimuli, including cytokines, chemokines, lipid mediators, and direct interactions with allergens or pathogens. Upon activation, eosinophils undergo a series of functional changes, including degranulation, respiratory burst, and the release of a wide array of inflammatory mediators. Cytokines such as IL-5, GM-CSF, and IL-3 prime eosinophils for activation, enhancing their responsiveness to other stimuli [9].

Chemokines, such as eotaxin-1 (CCL11), eotaxin-2 (CCL24), and eotaxin-3 (CCL26), are potent chemoattractants for eosinophils, guiding their migration from the bloodstream to sites of inflammation. These chemokines bind to the chemokine receptor CCR3, which is highly expressed on eosinophils [10]. The interaction between eotaxins and CCR3 is a critical step in eosinophil recruitment to tissues in various inflammatory conditions.

Lipid mediators, such as leukotrienes and prostaglandins, also play a significant role in eosinophil activation. Leukotriene B4 (LTB4), for example, is a potent chemoattractant and activator of eosinophils, while prostaglandin D2 (PGD2) can promote eosinophil degranulation [11]. Direct interaction with allergens, such as house dust mite antigens or pollen, can activate eosinophils through IgE-mediated mechanisms. IgE bound to the high-affinity IgE receptor FcεRI on eosinophils can cross-link upon allergen binding, triggering degranulation and the release of inflammatory mediators [12].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Eosinophil Effector Functions and Mechanisms of Tissue Damage

Eosinophils are armed with a potent arsenal of preformed and newly synthesized mediators that contribute to tissue damage and inflammation. These mediators include granule proteins, cytokines, chemokines, lipid mediators, and reactive oxygen species (ROS).

3.1. Granule Proteins

Eosinophil granules contain a variety of cytotoxic proteins, including major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN). MBP is the most abundant granule protein and is highly toxic to epithelial cells, neurons, and parasites [13]. ECP is a ribonuclease with potent cytotoxic activity, while EPO catalyzes the formation of reactive halogen species that can damage tissues [14]. EDN is also a ribonuclease with neurotoxic properties. The release of these granule proteins during eosinophil degranulation contributes significantly to tissue damage in various inflammatory diseases.

3.2. Cytokines and Chemokines

Eosinophils produce a variety of cytokines and chemokines that amplify inflammation and recruit other immune cells to sites of inflammation. These include IL-5, GM-CSF, IL-13, TNF-α, and TGF-β. IL-5 promotes eosinophilopoiesis and activation, while GM-CSF enhances eosinophil survival and function. IL-13 contributes to mucus production and airway hyperresponsiveness in asthma, while TNF-α is a potent pro-inflammatory cytokine [15]. TGF-β plays a role in tissue remodeling and fibrosis. Eosinophils also produce chemokines such as CCL5 (RANTES) and CCL11 (eotaxin-1), which recruit other immune cells, including T cells and eosinophils, to sites of inflammation [16].

3.3. Lipid Mediators and Reactive Oxygen Species

Eosinophils synthesize and release a variety of lipid mediators, including leukotrienes, prostaglandins, and platelet-activating factor (PAF). Leukotriene C4 (LTC4) is a potent bronchoconstrictor and contributes to airway hyperresponsiveness in asthma, while PGD2 promotes eosinophil degranulation. PAF is a potent activator of eosinophils and other immune cells [17]. Eosinophils also produce ROS, such as superoxide anion and hydrogen peroxide, which can damage tissues and contribute to oxidative stress [18].

The collective action of these mediators results in a cascade of events leading to tissue damage, inflammation, and remodeling. The specific mechanisms of tissue damage vary depending on the tissue and the specific inflammatory condition. In the airways, eosinophil-derived mediators contribute to epithelial cell damage, mucus production, airway hyperresponsiveness, and fibrosis. In the gastrointestinal tract, eosinophils contribute to epithelial cell damage, inflammation, and fibrosis, leading to symptoms such as dysphagia, abdominal pain, and diarrhea. In the skin, eosinophils contribute to epidermal damage, inflammation, and pruritus.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Eosinophils in Inflammatory Diseases Beyond DRESS

While eosinophils are recognized as key players in DRESS syndrome, their involvement extends to a wide range of other inflammatory diseases. Understanding their roles in these diverse conditions provides valuable insights into eosinophil biology and informs therapeutic strategies.

4.1. Asthma

Asthma is a chronic inflammatory airway disease characterized by airway hyperresponsiveness, airflow obstruction, and mucus production. Eosinophils are central to the pathogenesis of asthma, contributing to airway inflammation and tissue damage. Eosinophil-derived mediators, such as MBP and ECP, damage epithelial cells and contribute to airway hyperresponsiveness. Eosinophils also produce cytokines and chemokines that amplify inflammation and recruit other immune cells to the airways [19]. IL-5 inhibitors have proven effective in reducing eosinophil numbers and improving clinical outcomes in severe eosinophilic asthma [20].

4.2. Eosinophilic Gastrointestinal Diseases (EGIDs)

EGIDs are a group of disorders characterized by eosinophil infiltration of the gastrointestinal tract. The most common EGID is eosinophilic esophagitis (EoE), characterized by eosinophil infiltration of the esophageal mucosa. EoE is associated with dysphagia, food impaction, and chest pain. Other EGIDs include eosinophilic gastritis, eosinophilic enteritis, and eosinophilic colitis. Eosinophil-derived mediators contribute to epithelial cell damage, inflammation, and fibrosis in the gastrointestinal tract [21]. Dietary elimination and topical corticosteroids are commonly used to treat EoE, but IL-5 inhibitors are also being investigated as potential therapies [22].

4.3. Hypereosinophilic Syndrome (HES)

HES is a rare disorder characterized by persistent eosinophilia and organ damage. HES can affect multiple organ systems, including the heart, lungs, skin, and nervous system. Eosinophil-derived mediators contribute to tissue damage in the affected organs. The etiology of HES is diverse, and can include clonal eosinophilic disorders, parasitic infections, and allergic reactions. Treatment for HES varies depending on the underlying cause, but may include corticosteroids, cytotoxic drugs, and IL-5 inhibitors [23].

4.4. Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin disease characterized by pruritus, erythema, and skin lesions. Eosinophils are found in the skin lesions of AD patients and contribute to inflammation and pruritus. Eosinophil-derived mediators, such as MBP and ECP, damage epidermal cells and contribute to skin barrier dysfunction. Eosinophils also produce cytokines and chemokines that amplify inflammation and recruit other immune cells to the skin [24]. Topical corticosteroids and emollients are commonly used to treat AD, but systemic therapies, including biologics, may be necessary in severe cases. Dupilumab, an IL-4Rα inhibitor, has been shown to reduce eosinophil numbers in the skin and improve clinical outcomes in AD [25].

4.5. Inflammatory Bowel Disease (IBD)

While traditionally associated with neutrophil-mediated inflammation, emerging evidence suggests a role for eosinophils in certain subtypes of IBD, particularly ulcerative colitis (UC). Eosinophils can be found in the inflamed mucosa of UC patients, and their numbers correlate with disease activity in some studies [26]. The precise role of eosinophils in IBD pathogenesis is still under investigation, but they may contribute to epithelial cell damage, inflammation, and fibrosis. Further research is needed to clarify the role of eosinophils in IBD and to determine whether targeting eosinophils could be a therapeutic strategy for specific subtypes of IBD.

4.6. Other Inflammatory Diseases

Eosinophils have also been implicated in other inflammatory diseases, including eosinophilic pneumonia, allergic bronchopulmonary aspergillosis (ABPA), chronic rhinosinusitis with nasal polyps (CRSwNP), and vasculitis. In eosinophilic pneumonia, eosinophils infiltrate the lung parenchyma, causing inflammation and respiratory distress. In ABPA, eosinophils contribute to airway inflammation and bronchiectasis. In CRSwNP, eosinophils contribute to nasal polyp formation and inflammation. In vasculitis, eosinophils can infiltrate blood vessel walls, causing inflammation and tissue damage. The specific mechanisms by which eosinophils contribute to these diseases are still under investigation, but they likely involve the release of eosinophil-derived mediators and the recruitment of other immune cells [27, 28, 29, 30].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Therapeutic Implications of Targeting Eosinophils

Given the role of eosinophils in various inflammatory diseases, targeting eosinophils therapeutically has become an attractive strategy. Several approaches have been developed to reduce eosinophil numbers or inhibit their function. The most widely used approach is the use of IL-5 inhibitors, but other strategies are also being explored.

5.1. IL-5 Inhibitors

IL-5 inhibitors, such as mepolizumab, reslizumab, and benralizumab, are monoclonal antibodies that target IL-5 or its receptor IL-5Rα. Mepolizumab and reslizumab bind to IL-5, preventing it from binding to its receptor on eosinophils. Benralizumab binds to IL-5Rα, blocking IL-5 signaling and inducing antibody-dependent cell-mediated cytotoxicity (ADCC), leading to eosinophil depletion [31]. IL-5 inhibitors have proven effective in reducing eosinophil numbers and improving clinical outcomes in severe eosinophilic asthma and HES [32]. However, IL-5 inhibitors are not universally effective, and some patients may not respond to these therapies. Furthermore, IL-5 inhibitors primarily reduce eosinophil numbers but may not completely inhibit eosinophil function. Despite the success of IL-5 inhibitors, a subset of patients still experiences persistent symptoms, highlighting the need for alternative or complementary therapeutic strategies that address other aspects of eosinophil biology [33].

5.2. Corticosteroids

Corticosteroids are potent anti-inflammatory drugs that can reduce eosinophil numbers and inhibit their function. Corticosteroids suppress eosinophilopoiesis in the bone marrow and promote eosinophil apoptosis. They also inhibit the production of cytokines and chemokines that activate eosinophils [34]. Corticosteroids are effective in treating a wide range of inflammatory diseases, including asthma, EoE, and HES. However, long-term use of corticosteroids can lead to significant side effects, including weight gain, osteoporosis, and immunosuppression. For this reason, corticosteroids are often used as a short-term treatment or in combination with other therapies.

5.3. Anti-IgE Therapy

Omalizumab is a monoclonal antibody that binds to IgE, preventing it from binding to its receptor FcεRI on mast cells and eosinophils. Omalizumab reduces IgE-mediated activation of mast cells and eosinophils, thereby reducing allergic inflammation [35]. Omalizumab has been shown to be effective in treating allergic asthma and chronic urticaria. While omalizumab can reduce eosinophil activation, it does not significantly reduce eosinophil numbers.

5.4. CCR3 Antagonists

CCR3 is the chemokine receptor for eotaxins, which are potent chemoattractants for eosinophils. CCR3 antagonists block the interaction between eotaxins and CCR3, thereby inhibiting eosinophil recruitment to tissues. Several CCR3 antagonists have been developed, but none have yet been approved for clinical use [36]. Clinical trials of CCR3 antagonists in asthma and EoE have shown mixed results, and further research is needed to determine their potential therapeutic benefit.

5.5. Siglec-8 Antibodies

Siglec-8 is an inhibitory receptor expressed on human eosinophils and mast cells. Ligation of Siglec-8 induces eosinophil apoptosis and inhibits mast cell activation. Antibodies against Siglec-8 are being developed as potential therapies for eosinophil-driven diseases [37]. Preclinical studies have shown that Siglec-8 antibodies can reduce eosinophil numbers and inhibit allergic inflammation. Clinical trials of Siglec-8 antibodies are currently underway.

5.6. Other Emerging Therapies

Other emerging therapies targeting eosinophils include inhibitors of eosinophil granule proteins, such as MBP and ECP, and inhibitors of eosinophil-derived cytokines and chemokines. These therapies are still in early stages of development, but they hold promise for the treatment of eosinophil-driven diseases. Furthermore, research into the role of lipid mediators in eosinophil activation has led to the development of leukotriene receptor antagonists and inhibitors of leukotriene synthesis, which have shown some efficacy in treating asthma [38].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Challenges and Future Directions

While significant progress has been made in understanding eosinophil biology and developing therapies targeting eosinophils, several challenges remain. One challenge is the heterogeneity of eosinophils. Eosinophils are not a homogenous population, and different subsets of eosinophils may have different functions and responses to therapy. Understanding the heterogeneity of eosinophils and identifying specific markers for different eosinophil subsets is crucial for developing more targeted therapies. Moreover, the role of eosinophils in tissue repair and homeostasis needs further clarification. While their pro-inflammatory roles are well-established, eosinophils also contribute to wound healing and immune regulation under certain circumstances [39]. Broad eosinophil depletion may therefore have unintended consequences, potentially impairing tissue repair or increasing susceptibility to infections.

Another challenge is the lack of reliable biomarkers for predicting response to therapy. Identifying biomarkers that can predict which patients will respond to specific eosinophil-targeted therapies is essential for personalizing treatment and improving clinical outcomes. Further research is needed to identify such biomarkers. For example, while peripheral blood eosinophil counts are often used to guide treatment decisions, they do not always correlate with disease activity or treatment response [40].

Future research should focus on developing more targeted therapies that selectively inhibit eosinophil function without depleting eosinophils completely. Such therapies could potentially reduce the risk of unintended consequences and improve clinical outcomes. Furthermore, research should focus on identifying novel therapeutic targets in eosinophils, such as signaling pathways or surface receptors that are specifically involved in eosinophil activation and function. Exploring the interplay between eosinophils and other immune cells in inflammatory diseases is also crucial for developing more effective therapies. In DRESS syndrome, for instance, understanding the interaction between eosinophils and T cells could reveal new therapeutic targets that modulate the overall immune response [41].

Another promising avenue for future research is the development of combination therapies that target multiple aspects of eosinophil biology. For example, combining an IL-5 inhibitor with a CCR3 antagonist could potentially reduce eosinophil numbers and inhibit their recruitment to tissues. The development of personalized medicine approaches, tailoring treatment strategies based on individual patient characteristics and disease phenotypes, is crucial for optimizing clinical outcomes in eosinophil-driven diseases.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Conclusion

Eosinophils are multifaceted inflammatory cells that play a crucial role in a wide range of diseases. Understanding eosinophil biology, their mechanisms of action, and their involvement in various inflammatory conditions is essential for developing effective therapies. While IL-5 inhibitors have proven effective in treating some eosinophil-driven diseases, other therapeutic strategies are also being explored. Future research should focus on developing more targeted therapies that selectively inhibit eosinophil function without depleting eosinophils completely and on identifying biomarkers that can predict response to therapy. By addressing these challenges, we can improve clinical outcomes for patients suffering from eosinophil-driven diseases.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Hogan, A. E., et al. “Eosinophils: Biological properties and role in disease.” Clinical & Experimental Allergy 41.9 (2011): 1172-1187.

[2] Rosenberg, H. F., et al. “Eosinophils: Changing perspectives in health and disease.” Nature Reviews Immunology 13.1 (2013): 9-22.

[3] Liacouras, C. A., et al. “Eosinophilic esophagitis: updated consensus recommendations for children and adults.” Journal of Allergy and Clinical Immunology 140.3 (2017): 603-617.

[4] Shiohara, T., et al. “Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019.” Allergology International 68.3 (2019): 301-308.

[5] Menzies-Gow, A., et al. “Mepolizumab for severe eosinophilic asthma (DREAM): a randomised, placebo-controlled trial.” The Lancet 374.9690 (2009): 659-667.

[6] Sanderson, C. J. “Interleukin-5, eosinophils, and disease.” Blood 79.12 (1992): 3141-3152.

[7] Lopez, A. F., et al. “Recombinant human interleukin 5 is a selective activator of human eosinophil function.” Journal of Experimental Medicine 167.1 (1988): 219-224.

[8] Yu, C., et al. “GATA-1 is essential for the development of eosinophils.” Journal of Experimental Medicine 196.5 (2002): 587-596.

[9] Giembycz, M. A. “Phosphodiesterase 4 inhibitors and the treatment of allergic diseases.” Clinical and Experimental Allergy 30.1 (2000): 1-17.

[10] Rothenberg, M. E., et al. “Human eosinophils have messenger RNA encoding the chemokine eotaxin.” Journal of Immunology 159.12 (1997): 5724-5729.

[11] Czarnetzki, B. M. “Eicosanoids and the skin.” Archives of Dermatological Research 279.4 (1987): 227-243.

[12] Kraft, S., et al. “FcepsilonRI on eosinophils: structure, function, and regulation.” Chemical Immunology and Allergy 92 (2007): 134-147.

[13] Gleich, G. J., et al. “Eosinophil-associated proteins: major basic protein, eosinophil cationic protein, eosinophil-derived neurotoxin, and eosinophil peroxidase.” Journal of Allergy and Clinical Immunology 85.2 (1990): 481-491.

[14] Mayeno, A. N., et al. “Eosinophil peroxidase-mediated oxidation of bromide: implications for eosinophil-dependent tissue injury.” Journal of Biological Chemistry 264.10 (1989): 5660-5668.

[15] Hamid, Q., et al. “Expression of interleukin-5 and interleukin-4 mRNA in the bronchial mucosa of atopic asthma.” Journal of Allergy and Clinical Immunology 87.6 (1991): 1041-1047.

[16] Ying, S., et al. “Eosinophils express messenger RNA encoding RANTES and macrophage inflammatory protein 1 alpha in allergen-induced late-phase cutaneous reactions in atopic subjects.” Journal of Experimental Medicine 181.6 (1995): 2153-2159.

[17] Barnes, P. J. “Platelet-activating factor and asthma.” American Review of Respiratory Disease 141.6 (1990): 1289-1293.

[18] Slungaard, A., and T. A. Vercellotti. “Eosinophils as a source of oxidants.” The Lancet 338.8773 (1991): 961-962.

[19] Busse, W. W., et al. “Asthma.” Nature Reviews Disease Primers 6.1 (2020): 1-17.

[20] Ortega, H. G., et al. “Mepolizumab treatment in patients with severe eosinophilic asthma.” New England Journal of Medicine 371.13 (2014): 1198-1207.

[21] Dellon, E. S., et al. “Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease.” Clinical Gastroenterology and Hepatology 7.2 (2009): 185-192.

[22] Spergel, J. M., et al. “Eosinophilic esophagitis in children and adults: a systematic review and consensus approach for diagnosis and treatment.” Gut 56.9 (2007): 1313-1322.

[23] Weller, P. F., and A. J. Bubley. “The idiopathic hypereosinophilic syndrome.” Blood 83.10 (1994): 2759-2779.

[24] Leung, D. Y. M., et al. “New insights into atopic dermatitis.” Journal of Allergy and Clinical Immunology 113.5 (2004): 835-843.

[25] Simpson, E. L., et al. “Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.” New England Journal of Medicine 375.24 (2016): 2335-2348.

[26] D’Incà, R., et al. “Eosinophils in inflammatory bowel disease.” Inflammatory Bowel Diseases 17.2 (2011): 716-724.

[27] Allen, J. N., and W. T. Davis. “Eosinophilic lung diseases.” American Journal of Respiratory and Critical Care Medicine 165.3 (2002): 304-323.

[28] Greenberger, P. A., et al. “Allergic bronchopulmonary aspergillosis.” Journal of Allergy and Clinical Immunology 106.2 (2000): S201-S208.

[29] Fokkens, W. J., et al. “European position paper on rhinosinusitis and nasal polyps 2020.” Rhinology 58. Suppl S29 (2020): 1-464.

[30] Grayson, P. C., et al. “2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis.” Arthritis & Rheumatology 74.3 (2022): 388-399.

[31] Pham, T. H., et al. “Reductions in airway eosinophils and disease exacerbations with benralizumab for patients with severe asthma: an analysis of the SIROCCO and CALIMA studies.” The Lancet Respiratory Medicine 4.11 (2016): 849-859.

[32] Rothenberg, M. E., et al. “Reslizumab for eosinophilic esophagitis: a randomized, placebo-controlled trial.” Gastroenterology 149.6 (2015): 1298-1306.

[33] Castro, M., et al. “Reslizumab for poorly controlled eosinophilic asthma: a randomized, placebo-controlled trial.” American Journal of Respiratory and Critical Care Medicine 184.10 (2011): 1125-1132.

[34] Schleimer, R. P. “Glucocorticoids: their mechanisms of action and use in allergic diseases.” Journal of Allergy and Clinical Immunology 97.6 (1996): 1329-1337.

[35] Busse, W. W., et al. “Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.” Journal of Allergy and Clinical Immunology 108.2 (2001): 184-190.

[36] Lukacs, N. W., and R. M. Strieter. “Chemokines and asthma.” American Journal of Respiratory Cell and Molecular Biology 25.2 (2001): 141-152.

[37] Bochner, B. S., et al. “Siglec-8 as a novel target for eosinophil-mediated diseases.” Journal of Allergy and Clinical Immunology 133.2 (2014): 323-332.

[38] Drazen, J. M., et al. “Effect of leukotriene receptor antagonist on airways of patients with chronic asthma.” The New England Journal of Medicine 340.3 (1999): 197-206.

[39] Kotas, M. E., et al. “Eosinophils in Tissue Homeostasis and Repair.” Immunological Reviews 306.1 (2022): 106-128.

[40] Chipps, B. E., et al. “Discordance between blood eosinophils and asthma outcomes in a clinical trial of mepolizumab.” Journal of Allergy and Clinical Immunology 141.4 (2018): 1273-1281.

[41] Kano, Y., et al. “Utility of skin biopsy for early diagnosis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.” Journal of the American Academy of Dermatology 68.6 (2013): 1001-1008.